We continue to invest heavily to meet our client's growth goals. These investments have included headcount increases, travel primarily related to Discover, increased clinical costs at off-campus classroom and laboratory sites due to the nursing shortage, technology services both in headcount and license fees as a result of new technology requests by our partners, and costs related to the new hybrid locations as we open five sites in the year ended December 31st, 2023, four sites in the six months added June 30th, 2024, and more will open later in 2024.

Aug 6, 2024 / CFO / receipt, needs a key / Dan Backus, CFO | earnings call 2024-08-06 | transcript 1bb008f2-2c3e-4c7e-acd3-5f4e9e7361b8 | chars 19745-20303 | segment 19

These investments include headcount increases, travel primarily related to Discover, increased clinical costs at off-campus classroom and laboratory sites due to the nursing shortage, technology services both in headcount and licensees fees as a result of new technology requests by our partners and costs related to the new hybrid locations as we opened five sites and the year ended December 31st, 2023.

May 7, 2024 / CFO / receipt, needs a key / Dan Backus, CFO | earnings call 2024-05-07 | transcript 1d19f4e7-7a28-426a-a9b3-a853b8986795 | chars 17406-17811 | segment 17

These investments include headcount increases, travel primarily related to Discover, increased clinical costs at off-campus classroom and laboratory sites due to the nursing shortage, technology services both in headcount and licensees fees as a result of new technology requests by our partners, and costs related to the new hybrid locations as we opened five sites and the year ended December 31st, 2023.

May 7, 2024 / CFO / receipt, needs a key / Dan Backus, CFO | earnings call 2024-05-07 | transcript 1d19f4e7-7a28-426a-a9b3-a853b8986795 | chars 51901-52307 | segment 52